MedTrace Logo

FDG an Myocardial Infarction: The PIAF Trial

NCT05138718 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2041

Last updated 2021-12-01

No results posted yet for this study

Summary

In order to define distinct and reliable arterial 18Fluorodeoxyglucose (FDG) thresholds identifying patients at risk for cardiovascular events, patients with a history of myocardial infarction will be included in this international multicenter trial. Non-enhanced whole-body FDG PET/CT will be performed in all patients and the arterial FDG uptake in the carotid arteries as well as the aorta will be quantified by calculating different uptake parameters. In addition, FDG uptake in hematopoietic tissues (spleen, bone marrow), visceral adipose tissue (VAT) and different brain regions (e. g. amygdala) will be measured.

Furthermore, specific blood biomarkers including genetic biomarkers, which are linked to atherosclerotic disease with predictive power for future cardiovascular events, will be analyzed in a subgroup of patients. In part 2 of the trial, a 4-year follow-up period will be analyzed with a focus on the prediction of cardiovascular events (acute coronary syndrome, non-fatal ischemic stroke, ischemic cardiac death, other causes of death, coronary/vascular revascularization, new-onset of angina, symptomatic peripheral arterial disease and heart failure).

The predictive value of the arterial, hematopoietic and cerebral FDG uptake parameters as well as of the specific blood and genetic biomarkers will be determined.

Conditions

  • History of Myocardial Infarction

Interventions

DIAGNOSTIC_TEST

18F-FDG PET/CT

Perform a 18F-FDG PET/CT to patients with history of myocardial infarction

Sponsors & Collaborators

  • International Atomic Energy Agency

    lead OTHER_GOV

Principal Investigators

  • Francesco Giammarile, MD, PhD · International Atomic Energy Agency

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2025-07-01
Completion
2026-07-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05138718 on ClinicalTrials.gov